🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#CircAHA24 ATTRibute-CM Extension: Continuous acoramidis use in ATTR-CM reduced mortality and hospitalizations with sustained benefits and no new safety issues at 42 months ahajrnls.org/4ezTmcX

And it’s a wrap! #AHA2024 #Chicago Had the pleasure to present our work on ATTR genetic carriers 🫀 & reconnect with friends and mentors from Stanford CVI and American University of Beirut !

Excited to see the second ever drug approval for #ATTR cardiomyopathy. Another triumph for science 🧪 and great news for patients. Congratulations to all who have been involved in this journey! #ATTRUBY BridgeBio Pharma Martha Grogan MD Kevin Alexander Kenneth Mahaffey Paul Cheng

Study can be found here: tandfonline.com/doi/full/10.10… (15/15) Paul Cheng Ronald Witteles Kevin Alexander Martha Grogan MD Pr Thibaud DAMY MD, PhD Ahmad Masri The International Society Of Amyloidosis Brett Sperry, MD Margot Davis Frederick L Ruberg Sanjiv J. Shah, MD Sharmila Dorbala

Did you know African American communities face a higher risk of transthyretin cardiac amyloidosis, often misdiagnosed as heart failure? Early screening & risk recognition are key to better outcomes. Kevin Alexander #HeartMonth Episode 98 drops next week— medcast.stanford.edu

🚨 Acoramidis ⬇️⬇️ Hospitalizations in #ATTR cardiomyopathy 🫀 Part 2 of my discussion with Dr. Kevin Alexander is live! (and the link for Part 1 is back up and running ☺️) Thanks to Kevin Alexander, DocWire News, and CardioNerds 🤓 #Amyloidosis #AHA24 docwirenews.com/post/acoramidi…

Why is heart failure & cardiac amyloidosis under-diagnosed in African American communities? 🫀 Dr. Alexander discusses the latest treatments, AI’s role in early detection & the need for equitable care. #HeartMonth Listen to Ep 98 of @StanfordMedcast🎧 now medcast.stanford.edu

I’m excited to be speaking at the AHA’s National AL-Amyloidosis Patient-to-Provider Connection Forum March 12th! Hope you can join us! 🔗 to register: heart.zoom.us/meeting/regist… #Amyloidosis #HeartHealth #AHAQI American Heart Association Amyloidosis Speakers Bureau Amyloidosis Research Consortium Amyloidosis Support

And then there were 3! Ronald Witteles Ahmad Masri Martha Grogan MD Mazen Hanna Brett Sperry, MD Kevin Alexander Yevgeniy Brailovsky DO MSc FACC Melissa Lyle Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Justin L. Grodin investors.alnylam.com/press-release?…

Why is heart failure & cardiac amyloidosis under-diagnosed in African American communities? 🫀 Dr. Alexander discusses the latest treatments, AI’s role in early detection & the need for equitable care. #HeartHealth Listen to Ep 98 of Stanford Medcast ➡️ medcast.stanford.edu

Please share this exciting and interactive Amyloid case based seminar w/your fellow Amyloid champions and trainees. Brett Sperry, MD Mazen Hanna Melissa Lyle Martha Grogan MD Ahmad Masri Yevgeniy Brailovsky DO MSc FACC Michelle Kittleson MD PhD Ronald Witteles Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Kevin Alexander

🫀Therapeutic options for ATTR-CM are expanding rapidly, yet diagnostic delays remain significant.👇Our latest JACC Journals studies uncover geographic, socioeconomic and racial disparities in timely ATTR-CM diagnosis and outcomes, across both Stanford and national CDC cohorts.

Systemic efforts are needed for early diagnosis, enabling all populations to benefit from breakthrough treatments. For more details: 1) jacc.org/doi/abs/10.101… 2) jacc.org/doi/abs/10.101… Kevin Alexander Ronald Witteles Xiaokang_Wu JACC Journals #JACCHF

19a) A final analysis from #ATTRibute_CM, led by Kevin Alexander, evaluated the stability & improvement in #NYHA class on acoramidis vs placebo. At 30mo, 35.9% of pts in the #acoramidis group and 53.0% of pts in the placebo group had worsened in NYHA Class or had missing values.

Incredibly proud of the ⁦Stanford Heart Failure, Cardiac Transplant and MCS⁩ team, with so many impactful presentations at #ISHLT2025. Honored to work with such a talented group! ⁦Jeff Teuteberg⁩ ⁦Erik Henricksen⁩ ⁦Christian O’Donnell MD⁩ ⁦Kevin Alexander⁩

Establishing repeatability, reproducibility, & accuracy of imaging metrics is paramount for use in pivotal multicenter #amyloidosis trials. jacc.org/doi/10.1016/j.… #JACCIMG #cvImaging #CardioTwitter #CardioOnc Sharmila Dorbala Kevin Alexander Michele Emdin

New data from #ATTRibuteCM presented at #HeartFailure2025 Intriguing analysis by Kevin Alexander High-affinity TTR stabilizer acoramidis potentially associated with lower risks of AF/AFL events in #ATTRCM #MedIQHF2025

👑 Marianna Fontana new data at #HeartFailure2025 from #ATTRibuteCM Exploring effects of acoramidis on functional capacity & QOL in patients with variant ATTR-CM 6-minute walking distance - 87m (!) mean increase KCCQ health status gain - 20pt (!) mean increase #MedIQHF2025

How do patients with #ATTRCM die? New insights from #ATTRibuteCM at #HeartFailure2025 Kevin Alexander Ahmad Masri #MedIQHF2025

New research featuring #StanDOM's Gracia Fahed, Kevin Alexander, Ronald Witteles, Francois Haddad & Gabriela Spencer-Bonilla, highlights how socioeconomic disparities hinder early detection of transthyretin cardiac amyloidosis. stan.md/43CB1IL